Valneva (VALN) Competitors $6.34 -0.07 (-1.15%) As of 05/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. VCEL, NAMS, AAPG, KYMR, BHVN, DNLI, IBRX, HRMY, TWST, and BLTEShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Vericel (VCEL), NewAmsterdam Pharma (NAMS), Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), Biohaven (BHVN), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Harmony Biosciences (HRMY), Twist Bioscience (TWST), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Vericel NewAmsterdam Pharma Ascentage Pharma Group International Kymera Therapeutics Biohaven Denali Therapeutics ImmunityBio Harmony Biosciences Twist Bioscience Belite Bio Vericel (NASDAQ:VCEL) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Which has stronger valuation & earnings, VCEL or VALN? Vericel has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$238.54M8.67-$3.18M$0.031,369.00Valneva$186.06M2.89-$109.78M-$1.19-5.40 Do insiders and institutionals believe in VCEL or VALN? 11.4% of Valneva shares are held by institutional investors. 5.2% of Vericel shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor VCEL or VALN? Vericel received 313 more outperform votes than Valneva when rated by MarketBeat users. However, 66.67% of users gave Valneva an outperform vote while only 61.74% of users gave Vericel an outperform vote. CompanyUnderperformOutperformVericelOutperform Votes35561.74% Underperform Votes22038.26% ValnevaOutperform Votes4266.67% Underperform Votes2133.33% Which has more risk & volatility, VCEL or VALN? Vericel has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Does the media favor VCEL or VALN? In the previous week, Vericel had 6 more articles in the media than Valneva. MarketBeat recorded 6 mentions for Vericel and 0 mentions for Valneva. Vericel's average media sentiment score of 1.39 beat Valneva's score of 0.04 indicating that Vericel is being referred to more favorably in the media. Company Overall Sentiment Vericel Positive Valneva Neutral Do analysts rate VCEL or VALN? Vericel currently has a consensus price target of $60.86, suggesting a potential upside of 48.18%. Valneva has a consensus price target of $15.50, suggesting a potential upside of 141.25%. Given Valneva's higher possible upside, analysts clearly believe Valneva is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VCEL or VALN more profitable? Vericel has a net margin of 1.56% compared to Valneva's net margin of -4.35%. Vericel's return on equity of 1.48% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets Vericel1.56% 1.48% 0.96% Valneva -4.35%-3.93%-1.42% SummaryVericel beats Valneva on 12 of the 17 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$537.36M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-49.4230.5026.8419.71Price / Sales2.89400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book3.213.286.794.50Net Income-$109.78M-$72.17M$3.23B$248.18M7 Day Performance0.23%4.28%4.07%1.14%1 Month Performance-3.09%7.62%12.52%15.18%1 Year Performance-22.22%-28.15%16.83%6.55% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.0997 of 5 stars$6.43+0.2%$15.50+141.2%-22.2%$537.36M$186.06M-49.42700VCELVericel2.5508 of 5 stars$42.65+2.2%$60.86+42.7%-20.3%$2.14B$238.54M710.95300Positive NewsNAMSNewAmsterdam Pharma2.5095 of 5 stars$19.22+4.6%$43.00+123.7%-5.0%$2.11B$45.56M-10.224AAPGAscentage Pharma Group InternationalN/A$24.20-0.5%N/AN/A$2.11B$980.65M0.00600Positive NewsGap UpKYMRKymera Therapeutics2.7107 of 5 stars$32.17+7.0%$55.53+72.6%-14.7%$2.09B$47.07M-13.75170Analyst ForecastGap DownBHVNBiohaven3.487 of 5 stars$20.47+1.1%$62.54+205.5%-59.4%$2.09BN/A-2.19239Analyst DowngradeGap DownDNLIDenali Therapeutics4.4182 of 5 stars$14.80+3.0%$33.79+128.3%-31.5%$2.09B$330.53M-5.36430Analyst ForecastIBRXImmunityBio1.8581 of 5 stars$2.36+14.0%$12.19+416.4%-61.1%$2.08B$14.75M-2.57590Analyst UpgradeHigh Trading VolumeHRMYHarmony Biosciences4.7857 of 5 stars$35.65+4.7%$52.33+46.8%+16.4%$2.05B$744.85M16.90200Positive NewsTWSTTwist Bioscience4.2977 of 5 stars$32.95+6.9%$50.40+53.0%-35.4%$1.97B$347.68M-9.75990Positive NewsBLTEBelite Bio2.0486 of 5 stars$61.99+1.5%$96.67+55.9%+48.2%$1.97BN/A-55.8510News CoverageAnalyst RevisionGap Up Related Companies and Tools Related Companies VCEL Alternatives NAMS Alternatives AAPG Alternatives KYMR Alternatives BHVN Alternatives DNLI Alternatives IBRX Alternatives HRMY Alternatives TWST Alternatives BLTE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
